Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat
Abstract Background Atabecestat, a potent brain penetrable BACE1 inhibitor that reduces CSF amyloid beta (Aβ), was developed as an oral treatment for Alzheimer’s disease (AD). Elevated liver enzyme adverse events were reported in three studies although only one case met Hy’s law criteria to predict...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2023-09-01
|
| Saila: | BMC Genomics |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12864-023-09625-6 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|